A lot of people follow/know more than I, especially Biotech Jim! I don't have a position in the company though I've been interested in it for some time (at preferably much lower stock price).
With those caveats... I was surprised Omidria revenue growth held up! I was expecting a weak quarter. I realize everyone values 721 more (I don't disagree) however I thought a weak quarter would spook people even more then the reimbursement change coming in 2018.
News 
Market Data 
Discover 
AI
